Review
Accepted on 02 Mar 2026
Depemokimab and the twice-yearly regimen: pharmacological implications and therapeutic positioning in severe eosinophilic respiratory diseases
in Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders
Review
Accepted on 02 Mar 2026
in Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders
Original Research
Accepted on 02 Mar 2026
in Nephrology
Original Research
Accepted on 02 Mar 2026
in Inflammation
Original Research
Accepted on 02 Mar 2026
in Public Health Education and Promotion
Review
Accepted on 02 Mar 2026
in Molecular and Cellular Pathology
Original Research
Accepted on 02 Mar 2026
in Environmental Informatics and Remote Sensing
Review
Accepted on 02 Mar 2026
in Translational Neuroscience
Original Research
Accepted on 02 Mar 2026
in Environmental Psychology
Original Research
Accepted on 02 Mar 2026
in Breast Cancer
Original Research
Accepted on 02 Mar 2026
in Gastrointestinal Cancers: Colorectal Cancer
Original Research
Accepted on 02 Mar 2026
in Viral Immunology
Original Research
Accepted on 02 Mar 2026
in Molecular and Cellular Pathology
Original Research
Accepted on 02 Mar 2026
in Water and Artificial Intelligence
Original Research
Accepted on 02 Mar 2026
in Mucosal Immunity
Original Research
Accepted on 02 Mar 2026
in Obstetrics and Gynecology
Brief Research Report
Accepted on 02 Mar 2026
in Movement Disorders